Traws Pharma, Inc. (TRAW) Stock Competitors & Peer Comparison
See (TRAW) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TRAW | $0.61 | -9.18% | 5.6M | -0.49 | -$1.24 | N/A |
| VRTX | $479.96 | -1.17% | 122B | 25.53 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $669.88 | -1.01% | 69.2B | 14.73 | $45.63 | +0.54% |
| ARGX | $867.19 | +0.77% | 52.6B | 76.37 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $181.73 | -2.38% | 38.4B | -25.51 | -$7.07 | N/A |
| RVMDW | $8.66 | -6.76% | 36.7B | -2.07 | -$4.15 | N/A |
| ALNY | $272.86 | +2.01% | 36.4B | 49.13 | $5.55 | N/A |
| ONC | $316.02 | +1.28% | 33.2B | 69.48 | $4.47 | N/A |
Stock Comparison
TRAW vs VRTX Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, VRTX has a market cap of 122B. Regarding current trading prices, TRAW is priced at $0.61, while VRTX trades at $479.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas VRTX's P/E ratio is 25.53. In terms of profitability, TRAW's ROE is +4.90%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, TRAW is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check VRTX's competition here
TRAW vs VRNA Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, TRAW is priced at $0.61, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas VRNA's P/E ratio is -102.80. In terms of profitability, TRAW's ROE is +4.90%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, TRAW is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check VRNA's competition here
TRAW vs REGN Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, REGN has a market cap of 69.2B. Regarding current trading prices, TRAW is priced at $0.61, while REGN trades at $669.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas REGN's P/E ratio is 14.73. In terms of profitability, TRAW's ROE is +4.90%, compared to REGN's ROE of +0.14%. Regarding short-term risk, TRAW is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check REGN's competition here
TRAW vs ARGX Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, ARGX has a market cap of 52.6B. Regarding current trading prices, TRAW is priced at $0.61, while ARGX trades at $867.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas ARGX's P/E ratio is 76.37. In terms of profitability, TRAW's ROE is +4.90%, compared to ARGX's ROE of +0.22%. Regarding short-term risk, TRAW is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ARGX's competition here
TRAW vs SGEN Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, TRAW is priced at $0.61, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas SGEN's P/E ratio is -57.19. In terms of profitability, TRAW's ROE is +4.90%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, TRAW is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check SGEN's competition here
TRAW vs RVMD Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, RVMD has a market cap of 38.4B. Regarding current trading prices, TRAW is priced at $0.61, while RVMD trades at $181.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas RVMD's P/E ratio is -25.51. In terms of profitability, TRAW's ROE is +4.90%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, TRAW is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check RVMD's competition here
TRAW vs RVMDW Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, RVMDW has a market cap of 36.7B. Regarding current trading prices, TRAW is priced at $0.61, while RVMDW trades at $8.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas RVMDW's P/E ratio is -2.07. In terms of profitability, TRAW's ROE is +4.90%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, TRAW is more volatile compared to RVMDW. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check RVMDW's competition here
TRAW vs ALNY Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, ALNY has a market cap of 36.4B. Regarding current trading prices, TRAW is priced at $0.61, while ALNY trades at $272.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas ALNY's P/E ratio is 49.13. In terms of profitability, TRAW's ROE is +4.90%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, TRAW is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ALNY's competition here
TRAW vs ONC Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, ONC has a market cap of 33.2B. Regarding current trading prices, TRAW is priced at $0.61, while ONC trades at $316.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas ONC's P/E ratio is 69.48. In terms of profitability, TRAW's ROE is +4.90%, compared to ONC's ROE of +0.12%. Regarding short-term risk, TRAW is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ONC's competition here
TRAW vs ROIV Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, ROIV has a market cap of 24.5B. Regarding current trading prices, TRAW is priced at $0.61, while ROIV trades at $34.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas ROIV's P/E ratio is -35.00. In terms of profitability, TRAW's ROE is +4.90%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, TRAW is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ROIV's competition here
TRAW vs MRNA Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, MRNA has a market cap of 23.6B. Regarding current trading prices, TRAW is priced at $0.61, while MRNA trades at $59.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas MRNA's P/E ratio is -7.30. In terms of profitability, TRAW's ROE is +4.90%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, TRAW is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check MRNA's competition here
TRAW vs BNTX Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, BNTX has a market cap of 23.3B. Regarding current trading prices, TRAW is priced at $0.61, while BNTX trades at $92.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas BNTX's P/E ratio is -19.95. In terms of profitability, TRAW's ROE is +4.90%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, TRAW is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check BNTX's competition here
TRAW vs INSM Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, INSM has a market cap of 23.2B. Regarding current trading prices, TRAW is priced at $0.61, while INSM trades at $107.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas INSM's P/E ratio is -18.61. In terms of profitability, TRAW's ROE is +4.90%, compared to INSM's ROE of -1.30%. Regarding short-term risk, TRAW is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check INSM's competition here
TRAW vs INCY Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, INCY has a market cap of 23.1B. Regarding current trading prices, TRAW is priced at $0.61, while INCY trades at $117.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas INCY's P/E ratio is 15.54. In terms of profitability, TRAW's ROE is +4.90%, compared to INCY's ROE of +0.29%. Regarding short-term risk, TRAW is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check INCY's competition here
TRAW vs UTHR Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, UTHR has a market cap of 22.5B. Regarding current trading prices, TRAW is priced at $0.61, while UTHR trades at $529.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas UTHR's P/E ratio is 19.54. In terms of profitability, TRAW's ROE is +4.90%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, TRAW is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check UTHR's competition here
TRAW vs BGNE Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, TRAW is priced at $0.61, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas BGNE's P/E ratio is -22.55. In terms of profitability, TRAW's ROE is +4.90%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, TRAW is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check BGNE's competition here
TRAW vs DNA-WT Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, TRAW is priced at $0.61, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, TRAW's ROE is +4.90%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, TRAW is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check DNA-WT's competition here
TRAW vs NBIX Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, NBIX has a market cap of 17.4B. Regarding current trading prices, TRAW is priced at $0.61, while NBIX trades at $177.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas NBIX's P/E ratio is 25.00. In terms of profitability, TRAW's ROE is +4.90%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, TRAW is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check NBIX's competition here
TRAW vs GMAB Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, GMAB has a market cap of 17.1B. Regarding current trading prices, TRAW is priced at $0.61, while GMAB trades at $28.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas GMAB's P/E ratio is 20.08. In terms of profitability, TRAW's ROE is +4.90%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, TRAW is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check GMAB's competition here
TRAW vs BBIO Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, BBIO has a market cap of 15.8B. Regarding current trading prices, TRAW is priced at $0.61, while BBIO trades at $81.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas BBIO's P/E ratio is -21.59. In terms of profitability, TRAW's ROE is +4.90%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, TRAW is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check BBIO's competition here
TRAW vs ASND Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, ASND has a market cap of 15.6B. Regarding current trading prices, TRAW is priced at $0.61, while ASND trades at $252.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas ASND's P/E ratio is -104.03. In terms of profitability, TRAW's ROE is +4.90%, compared to ASND's ROE of -56.42%. Regarding short-term risk, TRAW is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ASND's competition here
TRAW vs JAZZ Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, JAZZ has a market cap of 15.3B. Regarding current trading prices, TRAW is priced at $0.61, while JAZZ trades at $249.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas JAZZ's P/E ratio is 18.93. In terms of profitability, TRAW's ROE is +4.90%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, TRAW is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check JAZZ's competition here
TRAW vs EXEL Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, EXEL has a market cap of 14B. Regarding current trading prices, TRAW is priced at $0.61, while EXEL trades at $55.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas EXEL's P/E ratio is 16.63. In terms of profitability, TRAW's ROE is +4.90%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, TRAW is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check EXEL's competition here
TRAW vs KRTX Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, TRAW is priced at $0.61, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas KRTX's P/E ratio is -28.09. In terms of profitability, TRAW's ROE is +4.90%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, TRAW is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check KRTX's competition here
TRAW vs MDGL Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, MDGL has a market cap of 12.4B. Regarding current trading prices, TRAW is priced at $0.61, while MDGL trades at $542.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas MDGL's P/E ratio is -41.85. In terms of profitability, TRAW's ROE is +4.90%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, TRAW is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check MDGL's competition here
TRAW vs BMRN Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, BMRN has a market cap of 11.4B. Regarding current trading prices, TRAW is priced at $0.61, while BMRN trades at $59.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas BMRN's P/E ratio is 28.42. In terms of profitability, TRAW's ROE is +4.90%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, TRAW is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check BMRN's competition here
TRAW vs AXSM Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, AXSM has a market cap of 11.4B. Regarding current trading prices, TRAW is priced at $0.61, while AXSM trades at $226.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas AXSM's P/E ratio is -57.87. In terms of profitability, TRAW's ROE is +4.90%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, TRAW is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check AXSM's competition here
TRAW vs RNAM Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, TRAW is priced at $0.61, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas RNAM's P/E ratio is -17.39. In terms of profitability, TRAW's ROE is +4.90%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, TRAW is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check RNAM's competition here
TRAW vs TECH Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, TECH has a market cap of 11.2B. Regarding current trading prices, TRAW is priced at $0.61, while TECH trades at $71.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas TECH's P/E ratio is 36.93. In terms of profitability, TRAW's ROE is +4.90%, compared to TECH's ROE of +0.05%. Regarding short-term risk, TRAW is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check TECH's competition here
TRAW vs SMMT Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, SMMT has a market cap of 10.5B. Regarding current trading prices, TRAW is priced at $0.61, while SMMT trades at $14.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas SMMT's P/E ratio is -8.44. In terms of profitability, TRAW's ROE is +4.90%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, TRAW is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check SMMT's competition here
TRAW vs ARWR Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, ARWR has a market cap of 10.1B. Regarding current trading prices, TRAW is priced at $0.61, while ARWR trades at $73.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas ARWR's P/E ratio is -33.33. In terms of profitability, TRAW's ROE is +4.90%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, TRAW is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ARWR's competition here
TRAW vs KRYS Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, KRYS has a market cap of 10B. Regarding current trading prices, TRAW is priced at $0.61, while KRYS trades at $336.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas KRYS's P/E ratio is 45.35. In terms of profitability, TRAW's ROE is +4.90%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, TRAW is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check KRYS's competition here
TRAW vs CYTK Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, CYTK has a market cap of 9.8B. Regarding current trading prices, TRAW is priced at $0.61, while CYTK trades at $80.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas CYTK's P/E ratio is -13.57. In terms of profitability, TRAW's ROE is +4.90%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, TRAW is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check CYTK's competition here
TRAW vs ABVX Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, ABVX has a market cap of 9.7B. Regarding current trading prices, TRAW is priced at $0.61, while ABVX trades at $133.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas ABVX's P/E ratio is -68.93. In terms of profitability, TRAW's ROE is +4.90%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, TRAW is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ABVX's competition here
TRAW vs RXDX Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, TRAW is priced at $0.61, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas RXDX's P/E ratio is -56.47. In terms of profitability, TRAW's ROE is +4.90%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, TRAW is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check RXDX's competition here
TRAW vs HALO Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, HALO has a market cap of 9.1B. Regarding current trading prices, TRAW is priced at $0.61, while HALO trades at $78.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas HALO's P/E ratio is 16.69. In terms of profitability, TRAW's ROE is +4.90%, compared to HALO's ROE of +1.26%. Regarding short-term risk, TRAW is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check HALO's competition here
TRAW vs KYMR Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, KYMR has a market cap of 9.1B. Regarding current trading prices, TRAW is priced at $0.61, while KYMR trades at $111.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas KYMR's P/E ratio is -31.46. In terms of profitability, TRAW's ROE is +4.90%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, TRAW is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check KYMR's competition here
TRAW vs NUVL Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, TRAW is priced at $0.61, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas NUVL's P/E ratio is -21.79. In terms of profitability, TRAW's ROE is +4.90%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, TRAW is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check NUVL's competition here
TRAW vs CRNX Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, TRAW is priced at $0.61, while CRNX trades at $83.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas CRNX's P/E ratio is -16.35. In terms of profitability, TRAW's ROE is +4.90%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, TRAW is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check CRNX's competition here
TRAW vs IONS Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, IONS has a market cap of 8.8B. Regarding current trading prices, TRAW is priced at $0.61, while IONS trades at $53.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas IONS's P/E ratio is -30.78. In terms of profitability, TRAW's ROE is +4.90%, compared to IONS's ROE of -0.59%. Regarding short-term risk, TRAW is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check IONS's competition here
TRAW vs IMGN Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, TRAW is priced at $0.61, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas IMGN's P/E ratio is -111.55. In terms of profitability, TRAW's ROE is +4.90%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, TRAW is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check IMGN's competition here
TRAW vs PTGX Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, PTGX has a market cap of 8.6B. Regarding current trading prices, TRAW is priced at $0.61, while PTGX trades at $135.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas PTGX's P/E ratio is -74.18. In terms of profitability, TRAW's ROE is +4.90%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, TRAW is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check PTGX's competition here
TRAW vs ALKS Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, ALKS has a market cap of 8.6B. Regarding current trading prices, TRAW is priced at $0.61, while ALKS trades at $52.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas ALKS's P/E ratio is 54.44. In terms of profitability, TRAW's ROE is +4.90%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, TRAW is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ALKS's competition here
TRAW vs BPMC Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, TRAW is priced at $0.61, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas BPMC's P/E ratio is -51.58. In terms of profitability, TRAW's ROE is +4.90%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, TRAW is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check BPMC's competition here
TRAW vs APGE Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, TRAW is priced at $0.61, while APGE trades at $134.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas APGE's P/E ratio is -30.98. In terms of profitability, TRAW's ROE is +4.90%, compared to APGE's ROE of -0.33%. Regarding short-term risk, TRAW is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check APGE's competition here
TRAW vs TGTX Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, TRAW is priced at $0.61, while TGTX trades at $53.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas TGTX's P/E ratio is 18.54. In terms of profitability, TRAW's ROE is +4.90%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, TRAW is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check TGTX's competition here
TRAW vs IMVT Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, IMVT has a market cap of 8.2B. Regarding current trading prices, TRAW is priced at $0.61, while IMVT trades at $39.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas IMVT's P/E ratio is -14.95. In terms of profitability, TRAW's ROE is +4.90%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, TRAW is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check IMVT's competition here
TRAW vs CERE Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, TRAW is priced at $0.61, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas CERE's P/E ratio is -16.47. In terms of profitability, TRAW's ROE is +4.90%, compared to CERE's ROE of -0.72%. Regarding short-term risk, TRAW is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check CERE's competition here
TRAW vs PCVX Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, PCVX has a market cap of 8B. Regarding current trading prices, TRAW is priced at $0.61, while PCVX trades at $57.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas PCVX's P/E ratio is -8.07. In terms of profitability, TRAW's ROE is +4.90%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, TRAW is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check PCVX's competition here
TRAW vs IBRX Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, IBRX has a market cap of 7.8B. Regarding current trading prices, TRAW is priced at $0.61, while IBRX trades at $7.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas IBRX's P/E ratio is -8.82. In terms of profitability, TRAW's ROE is +4.90%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, TRAW is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check IBRX's competition here
TRAW vs MTSR Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, TRAW is priced at $0.61, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas MTSR's P/E ratio is -23.58. In terms of profitability, TRAW's ROE is +4.90%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, TRAW is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check MTSR's competition here
TRAW vs RYTM Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, RYTM has a market cap of 7.2B. Regarding current trading prices, TRAW is priced at $0.61, while RYTM trades at $106.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas RYTM's P/E ratio is -33.42. In terms of profitability, TRAW's ROE is +4.90%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, TRAW is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check RYTM's competition here
TRAW vs MRUS Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, TRAW is priced at $0.61, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas MRUS's P/E ratio is -17.05. In terms of profitability, TRAW's ROE is +4.90%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, TRAW is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check MRUS's competition here
TRAW vs ACLX Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, TRAW is priced at $0.61, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas ACLX's P/E ratio is -28.27. In terms of profitability, TRAW's ROE is +4.90%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, TRAW is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ACLX's competition here
TRAW vs RETA Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, TRAW is priced at $0.61, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas RETA's P/E ratio is -66.29. In terms of profitability, TRAW's ROE is +4.90%, compared to RETA's ROE of +0.47%. Regarding short-term risk, TRAW is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check RETA's competition here
TRAW vs COGT Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, COGT has a market cap of 6.5B. Regarding current trading prices, TRAW is priced at $0.61, while COGT trades at $39.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas COGT's P/E ratio is -18.15. In terms of profitability, TRAW's ROE is +4.90%, compared to COGT's ROE of -0.83%. Regarding short-term risk, TRAW is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check COGT's competition here
TRAW vs PTCT Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, PTCT has a market cap of 6.5B. Regarding current trading prices, TRAW is priced at $0.61, while PTCT trades at $78.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas PTCT's P/E ratio is -33.48. In terms of profitability, TRAW's ROE is +4.90%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, TRAW is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check PTCT's competition here
TRAW vs PRAX Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, PRAX has a market cap of 6.4B. Regarding current trading prices, TRAW is priced at $0.61, while PRAX trades at $314.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas PRAX's P/E ratio is -22.77. In terms of profitability, TRAW's ROE is +4.90%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, TRAW is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check PRAX's competition here
TRAW vs CNTA Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, TRAW is priced at $0.61, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas CNTA's P/E ratio is -22.63. In terms of profitability, TRAW's ROE is +4.90%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, TRAW is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check CNTA's competition here
TRAW vs CGON Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, CGON has a market cap of 6.2B. Regarding current trading prices, TRAW is priced at $0.61, while CGON trades at $71.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas CGON's P/E ratio is -30.12. In terms of profitability, TRAW's ROE is +4.90%, compared to CGON's ROE of -0.23%. Regarding short-term risk, TRAW is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check CGON's competition here
TRAW vs BLTE Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, BLTE has a market cap of 6.1B. Regarding current trading prices, TRAW is priced at $0.61, while BLTE trades at $158.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas BLTE's P/E ratio is -81.73. In terms of profitability, TRAW's ROE is +4.90%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, TRAW is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check BLTE's competition here
TRAW vs SRRK Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, SRRK has a market cap of 6.1B. Regarding current trading prices, TRAW is priced at $0.61, while SRRK trades at $50.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas SRRK's P/E ratio is -14.11. In terms of profitability, TRAW's ROE is +4.90%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, TRAW is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check SRRK's competition here
TRAW vs LGND Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, LGND has a market cap of 5.9B. Regarding current trading prices, TRAW is priced at $0.61, while LGND trades at $300.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas LGND's P/E ratio is 35.25. In terms of profitability, TRAW's ROE is +4.90%, compared to LGND's ROE of +0.16%. Regarding short-term risk, TRAW is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check LGND's competition here
TRAW vs SYRE Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, SYRE has a market cap of 5.9B. Regarding current trading prices, TRAW is priced at $0.61, while SYRE trades at $101.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas SYRE's P/E ratio is -46.79. In terms of profitability, TRAW's ROE is +4.90%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, TRAW is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check SYRE's competition here
TRAW vs MIRM Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, MIRM has a market cap of 5.9B. Regarding current trading prices, TRAW is priced at $0.61, while MIRM trades at $116.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas MIRM's P/E ratio is -8.57. In terms of profitability, TRAW's ROE is +4.90%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, TRAW is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check MIRM's competition here
TRAW vs ERAS Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, ERAS has a market cap of 5.9B. Regarding current trading prices, TRAW is priced at $0.61, while ERAS trades at $19.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas ERAS's P/E ratio is -20.24. In terms of profitability, TRAW's ROE is +4.90%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, TRAW is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ERAS's competition here
TRAW vs CDTX Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, TRAW is priced at $0.61, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas CDTX's P/E ratio is -19.77. In terms of profitability, TRAW's ROE is +4.90%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, TRAW is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check CDTX's competition here
TRAW vs ABCM Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, TRAW is priced at $0.61, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, TRAW's ROE is +4.90%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, TRAW is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ABCM's competition here
TRAW vs ISEE Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, TRAW is priced at $0.61, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas ISEE's P/E ratio is -22.44. In terms of profitability, TRAW's ROE is +4.90%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, TRAW is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ISEE's competition here
TRAW vs APLS Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, TRAW is priced at $0.61, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas APLS's P/E ratio is 38.35. In terms of profitability, TRAW's ROE is +4.90%, compared to APLS's ROE of +0.40%. Regarding short-term risk, TRAW is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check APLS's competition here
TRAW vs XENE Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, XENE has a market cap of 5.2B. Regarding current trading prices, TRAW is priced at $0.61, while XENE trades at $66.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas XENE's P/E ratio is -14.05. In terms of profitability, TRAW's ROE is +4.90%, compared to XENE's ROE of -0.49%. Regarding short-term risk, TRAW is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check XENE's competition here
TRAW vs TVTX Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, TRAW is priced at $0.61, while TVTX trades at $55.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas TVTX's P/E ratio is -252.14. In terms of profitability, TRAW's ROE is +4.90%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, TRAW is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check TVTX's competition here
TRAW vs TERN Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, TRAW is priced at $0.61, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas TERN's P/E ratio is -51.41. In terms of profitability, TRAW's ROE is +4.90%, compared to TERN's ROE of -0.20%. Regarding short-term risk, TRAW is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check TERN's competition here
TRAW vs DFTX Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, TRAW is priced at $0.61, while DFTX trades at $43.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas DFTX's P/E ratio is N/A. In terms of profitability, TRAW's ROE is +4.90%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, TRAW is more volatile compared to DFTX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check DFTX's competition here
TRAW vs FOLD Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, TRAW is priced at $0.61, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas FOLD's P/E ratio is -161.00. In terms of profitability, TRAW's ROE is +4.90%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, TRAW is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check FOLD's competition here
TRAW vs CRSP Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, CRSP has a market cap of 4.5B. Regarding current trading prices, TRAW is priced at $0.61, while CRSP trades at $48.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas CRSP's P/E ratio is -9.20. In terms of profitability, TRAW's ROE is +4.90%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, TRAW is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check CRSP's competition here
TRAW vs AKRO Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, TRAW is priced at $0.61, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas AKRO's P/E ratio is -14.57. In terms of profitability, TRAW's ROE is +4.90%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, TRAW is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check AKRO's competition here
TRAW vs ALPN Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, TRAW is priced at $0.61, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas ALPN's P/E ratio is -101.52. In terms of profitability, TRAW's ROE is +4.90%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, TRAW is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ALPN's competition here
TRAW vs MANE Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, TRAW is priced at $0.61, while MANE trades at $111.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas MANE's P/E ratio is -33.79. In terms of profitability, TRAW's ROE is +4.90%, compared to MANE's ROE of -0.84%. Regarding short-term risk, TRAW is more volatile compared to MANE. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check MANE's competition here
TRAW vs CAI Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, TRAW is priced at $0.61, while CAI trades at $15.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas CAI's P/E ratio is -85.59. In terms of profitability, TRAW's ROE is +4.90%, compared to CAI's ROE of +0.06%. Regarding short-term risk, TRAW is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check CAI's competition here
TRAW vs ACAD Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, TRAW is priced at $0.61, while ACAD trades at $25.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas ACAD's P/E ratio is 12.30. In terms of profitability, TRAW's ROE is +4.90%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, TRAW is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ACAD's competition here
TRAW vs LEGN Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, LEGN has a market cap of 4.3B. Regarding current trading prices, TRAW is priced at $0.61, while LEGN trades at $23.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas LEGN's P/E ratio is -34.13. In terms of profitability, TRAW's ROE is +4.90%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, TRAW is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check LEGN's competition here
TRAW vs CELC Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, CELC has a market cap of 4.3B. Regarding current trading prices, TRAW is priced at $0.61, while CELC trades at $90.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas CELC's P/E ratio is -22.56. In terms of profitability, TRAW's ROE is +4.90%, compared to CELC's ROE of -2.45%. Regarding short-term risk, TRAW is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check CELC's competition here
TRAW vs OPT Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, TRAW is priced at $0.61, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas OPT's P/E ratio is -1.52. In terms of profitability, TRAW's ROE is +4.90%, compared to OPT's ROE of +1.18%. Regarding short-term risk, TRAW is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check OPT's competition here
TRAW vs VKTX Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, VKTX has a market cap of 4.2B. Regarding current trading prices, TRAW is priced at $0.61, while VKTX trades at $37.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas VKTX's P/E ratio is -8.78. In terms of profitability, TRAW's ROE is +4.90%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, TRAW is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check VKTX's competition here
TRAW vs DNTH Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, DNTH has a market cap of 4.2B. Regarding current trading prices, TRAW is priced at $0.61, while DNTH trades at $104.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas DNTH's P/E ratio is -24.46. In terms of profitability, TRAW's ROE is +4.90%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, TRAW is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check DNTH's competition here
TRAW vs EWTX Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, EWTX has a market cap of 4.2B. Regarding current trading prices, TRAW is priced at $0.61, while EWTX trades at $39.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas EWTX's P/E ratio is -23.38. In terms of profitability, TRAW's ROE is +4.90%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, TRAW is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check EWTX's competition here
TRAW vs MRTX Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, TRAW is priced at $0.61, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas MRTX's P/E ratio is -4.82. In terms of profitability, TRAW's ROE is +4.90%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, TRAW is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check MRTX's competition here
TRAW vs DYN Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, DYN has a market cap of 3.9B. Regarding current trading prices, TRAW is priced at $0.61, while DYN trades at $23.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas DYN's P/E ratio is -7.28. In terms of profitability, TRAW's ROE is +4.90%, compared to DYN's ROE of -0.58%. Regarding short-term risk, TRAW is more volatile compared to DYN. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check DYN's competition here
TRAW vs CPRX Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, TRAW is priced at $0.61, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas CPRX's P/E ratio is 12.30. In terms of profitability, TRAW's ROE is +4.90%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, TRAW is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check CPRX's competition here
TRAW vs RYZB Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, TRAW is priced at $0.61, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas RYZB's P/E ratio is -57.86. In terms of profitability, TRAW's ROE is +4.90%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, TRAW is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check RYZB's competition here
TRAW vs CBAY Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, TRAW is priced at $0.61, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas CBAY's P/E ratio is -32.81. In terms of profitability, TRAW's ROE is +4.90%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, TRAW is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check CBAY's competition here
TRAW vs ELVN Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, ELVN has a market cap of 3.7B. Regarding current trading prices, TRAW is priced at $0.61, while ELVN trades at $53.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas ELVN's P/E ratio is -30.94. In terms of profitability, TRAW's ROE is +4.90%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, TRAW is more volatile compared to ELVN. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ELVN's competition here
TRAW vs DNLI Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, DNLI has a market cap of 3.6B. Regarding current trading prices, TRAW is priced at $0.61, while DNLI trades at $23.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas DNLI's P/E ratio is -7.95. In terms of profitability, TRAW's ROE is +4.90%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, TRAW is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check DNLI's competition here
TRAW vs TLX Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, TLX has a market cap of 3.6B. Regarding current trading prices, TRAW is priced at $0.61, while TLX trades at $10.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas TLX's P/E ratio is -571.20. In terms of profitability, TRAW's ROE is +4.90%, compared to TLX's ROE of -0.02%. Regarding short-term risk, TRAW is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check TLX's competition here
TRAW vs SWTX Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, TRAW is priced at $0.61, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas SWTX's P/E ratio is -13.78. In terms of profitability, TRAW's ROE is +4.90%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, TRAW is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check SWTX's competition here
TRAW vs ADPT Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, ADPT has a market cap of 3.5B. Regarding current trading prices, TRAW is priced at $0.61, while ADPT trades at $22.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas ADPT's P/E ratio is -40.48. In terms of profitability, TRAW's ROE is +4.90%, compared to ADPT's ROE of -0.24%. Regarding short-term risk, TRAW is more volatile compared to ADPT. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ADPT's competition here
TRAW vs NAMS Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, NAMS has a market cap of 3.5B. Regarding current trading prices, TRAW is priced at $0.61, while NAMS trades at $30.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas NAMS's P/E ratio is -18.66. In terms of profitability, TRAW's ROE is +4.90%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, TRAW is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check NAMS's competition here
TRAW vs ALMS Comparison July 2026
TRAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TRAW stands at 5.6M. In comparison, ALMS has a market cap of 3.5B. Regarding current trading prices, TRAW is priced at $0.61, while ALMS trades at $28.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TRAW currently has a P/E ratio of -0.49, whereas ALMS's P/E ratio is -7.14. In terms of profitability, TRAW's ROE is +4.90%, compared to ALMS's ROE of -0.55%. Regarding short-term risk, TRAW is more volatile compared to ALMS. This indicates potentially higher risk in terms of short-term price fluctuations for TRAW.Check ALMS's competition here